By serving as the cofactor for the enzyme, activated factor Vll (FVIIa), tissue factor (TF) is critical for hemostasis. Preclinical and clinical data, however, have implicated TF in the progression and/or complications associated with a multitude of pathological conditions including atherothrombosis, ischemia/reperfusion injury, sepsis, acute lung injury/acute respiratory distress syndrome (ALI/ARDS), thrombotic microangiopathy (e.g. hemolytic uremic syndrome associated with E. coli verotoxin, certain drugs, and ricin toxicity), glomerulonephritis, antiphospholipid syndrome, inflammatory bowel disease, hepafic veno-occlusive disease (aka sinusoidal obstruction syndrome, associated with chemotherapy and following bone marrow transplantation), arthritis, organ transplant rejection, sickle cell anemia, cancer growth and metastasis, chemotherapy-associated thrombosis (e.g. thalidomide, lenalidomide) and post-surgical venous thromboembolic disease. Therefore the development of an agent(s) that could safely limit the action of TF would conceivably improve the medical therapy for many people.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HL112303-02
Application #
8464256
Study Section
Special Emphasis Panel (ZHL1-CSR-C)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$281,076
Indirect Cost
$96,158
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Vemuri, Chandu; Upadhya, Gundumi A; Arif, Batool et al. (2018) Antithrombin Perfluorocarbon Nanoparticles Improve Renal Allograft Function in a Murine Deceased Criteria Donor Model. Transplant Direct 4:e384
Chinnaraj, Mathivanan; Chen, Zhiwei; Pelc, Leslie A et al. (2018) Structure of prothrombin in the closed form reveals new details on the mechanism of activation. Sci Rep 8:2945
Chakraborty, Pradipta; Acquasaliente, Laura; Pelc, Leslie A et al. (2018) Interplay between conformational selection and zymogen activation. Sci Rep 8:4080
Girard, T J; Grunz, K; Lasky, N M et al. (2018) Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. J Thromb Haemost 16:2246-2257
Wu, Xiaobo; Hutson, Irina; Akk, Antonina M et al. (2018) Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy. J Immunol 200:2786-2797
Sivaraja, Mohanram; Pozzi, Nicola; Rienzo, Matthew et al. (2018) Reversible covalent direct thrombin inhibitors. PLoS One 13:e0201377
Barranco-Medina, Sergio; Murphy, Mary; Pelc, Leslie et al. (2017) Rational Design of Protein C Activators. Sci Rep 7:44596
Liszewski, M Kathryn; Java, Anuja; Schramm, Elizabeth C et al. (2017) Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol 12:25-52
Shen, Guomin; Cui, Weidong; Zhang, Hao et al. (2017) Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. Nat Struct Mol Biol 24:69-76
Chakraborty, Pradipta; Di Cera, Enrico (2017) Induced Fit Is a Special Case of Conformational Selection. Biochemistry 56:2853-2859

Showing the most recent 10 out of 87 publications